Boronic acid ester prodrugs and uses thereof
An unsubstituted, compound technology, applied in the field of boronate prodrugs and their uses, can solve the problems of tissue penetration or bursting, poor payload release, ineffective penetration and accumulation, suboptimal MM treatment, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0382] Methods of making compounds and polymers
[0383] The present disclosure describes methods for preparing polymers from the monomers described herein. In certain embodiments, the method of making a polymer comprises polymerizing the monomers described herein.
[0384] The present disclosure also describes a method of making a polymer comprising reacting an existing polymer with a compound described herein, wherein the existing polymer includes a reaction handle capable of reacting with X, and in the reacting step, capable of reacting with The reaction handle of the X reaction reacts with the X. In certain embodiments, the existing polymer is a polymer described herein. In certain embodiments, the existing polymer is an addition polymer (eg, polyethylene, polytetrafluoroethylene, polypropylene, polyisobutylene, polystyrene, polyacrylonitrile, polyvinyl chloride, polymethyl acrylate, polymethyl methacrylate, polybutadiene, chlorambucil, poly(cis-1,4-isoprene) or poly(tr...
Embodiment
[0483] In order that the present disclosure may be more fully understood, the following examples are illustrated. The synthetic and biological examples described in this application are provided to illustrate the compounds, pharmaceutical compositions, and methods provided herein, and should not be construed in any way to limit their scope.
[0484] DETAILED DESCRIPTION OF THE EMBODIMENTS
[0485] Rational design of boronate-based Btz prodrugs.
[0486]To construct Btz-loaded BBPs, linkers were first developed that made Btz sufficiently stable and inactive in circulation in vivo, but also released Btz "on demand" once in the tumor microenvironment. The structure of the linker should be chemically modifiable, which translates to tunable release rates depending on the end application—similar to the design strategies that have been reported for several drug conjugates. 40,41 Therefore, 1,2-diol azide linker A5 ( figure 1 , full synthesis details are described in SI). A5 conta...
PUM
| Property | Measurement | Unit |
|---|---|---|
| Boiling point | aaaaa | aaaaa |
| Boiling point | aaaaa | aaaaa |
| Diameter | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


